MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.

Explore MiniMed Group, Inc.'s upcoming IPO, market position in diabetes devices, and key financial risks. Click for this MMED ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...

Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Automated insulin delivery systems — a continuous glucose monitor, insulin pump, and algorithm — enable athletes to manage ...

Automated insulin delivery systems can help pregnant women with type 1 diabetes manage their glucose during gestation.

In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning ...

Smart rings can help predict oncoming illnesses like COVID before they start. But do you really need one to monitor your everyday health?